Dolutegravir for first-line antiretroviral therapy in low-income and middle-income countries: uncertainties and opportunities for implementation and research
A new first-line antiretroviral therapy (ART) regimen containing dolutegravir is being rolled-out in low-income and middle-income countries (LMICs). Studies from predominantly high-income settings have found that dolutegravir-based regimens have superior efficacy, tolerability and durability compare...
Main Authors: | Dorward, J, Lessells, R, Drain, P, Naidoo, K, De Oliveira, T, Pillay, Y, Abdool Karim, S, Garrett, N |
---|---|
Format: | Journal article |
Sprog: | English |
Udgivet: |
Elsevier
2018
|
Lignende værker
-
Viremia and HIV drug resistance among people receiving dolutegravir versus efavirenz-based first-line antiretroviral therapy
af: Dorward, J, et al.
Udgivet: (2024) -
Clinical outcomes after Viremia among people receiving dolutegravir vs efavirenz-based first-line antiretroviral therapy in South Africa
af: Asare, K, et al.
Udgivet: (2023) -
Curbing the rise of HIV drug resistance in low-income and middle-income countries: the role of dolutegravir-containing regimens
af: Inzaule, SC, et al.
Udgivet: (2019) -
Implementation and outcomes of dolutegravir-based first-line antiretroviral therapy for people with HIV in South Africa: a retrospective cohort study
af: Dorward, J, et al.
Udgivet: (2023) -
Urine tenofovir and dried blood spot tenofovir diphosphate concentrations and viraemia in people taking efavirenz and dolutegravir based antiretroviral therapy
af: Dorward, J, et al.
Udgivet: (2023)